Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)

NCT01841697 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

642

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Omarigliptin
DRUG: Sitagliptin
DRUG: Placebo to omarigliptin
DRUG: Placebo to Sitagliptin
DRUG: Open-label Metformin
DRUG: Open-label Glimepiride

Sponsor

Merck Sharp & Dohme LLC